Governance Imunon, Inc.

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

Executive Committee: Imunon, Inc.

Manager

Positions heldSince

Stacy Lindborg

54 year

Chief Executive Officer	2024-05-12
President	2024-05-12

Khursheed Anwer

65 year

Chief Tech/Sci/R&D Officer

2014-06-19

Kimberly Bragg

Comptroller/Controller/Auditor

Sebastien Hazard

54 year

Chief Tech/Sci/R&D Officer

2023-12-10

David Gaiero

46 year

Comptroller/Controller/Auditor	2024-05-31
Director of Finance/CFO	2024-05-31

Composition of the Board of Directors: Imunon, Inc.

Director

CommitteesSince

Michael Tardugno

74 year

Chairman

2014-10-06

Christine Pellizzari

57 year

Audit Committee	2021-12-20
Governance Committee Chair	2021-06-07
Nominating Committee Chair	2021-06-07
Compensation Committee	2023-03-21
Audit Committee Chair	2022-04-21
Compensation Committee Chair	2021-12-20

James Dentzer

58 year

Governance Committee	2022-10-02
Nominating Committee	2022-10-02
Audit Committee Chair	2022-10-02

Donald Braun

75 year

Compensation Committee	2015-12-14
Governance Committee
Nominating Committee

Frederick Fritz

74 year

Audit Committee
Compensation Committee Chair	2011-07-07

Stacy Lindborg

54 year

Compensation Committee

2021-06-03

Latest Appointments: Imunon, Inc.

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary	24-10-07	CI
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024	24-05-08	CI
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024	24-05-08	CI
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff	24-03-13	MT
Imunon, Inc. Announces Executive Changes	24-03-12	CI
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024	24-03-12	CI
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer	23-12-11	CI

More news

Former Officers and Directors: Imunon, Inc.

Insider

Positions held

SinceUntil

Jeffrey Church

Director of Finance/CFO	2010-07-07	2024-05-31
Investor Relations Contact	2011-07-12	2024-05-31
Corporate Secretary	2010-07-05	2024-05-31

Corinne Le Goff

Director/Board Member	2022-07-17	2024-03-14
Chief Executive Officer	2022-07-17	2024-03-14
President	2022-07-17	2024-03-14

Pok Yu Chow

Director/Board Member	2007-03-11	2023-06-13
Independent Dir/Board Member	2007-02-28	2023-06-13

Nicholas Borys

Chief Tech/Sci/R&D Officer

2007-09-30

2023-02-27

Robert Hooper

Director/Board Member	2010-08-02	2022-12-30
Independent Dir/Board Member	2010-06-30	2022-12-30

Constantine Kardaras

Comptroller/Controller/Auditor

2022-11-30

Andreas Voss

Director/Board Member	2015-12-14	2021-12-30
Independent Dir/Board Member	2015-12-14	2021-12-30

Jason G. Fewell

Corporate Officer/Principal

2014-05-31

2021-01-31

Alberto R. Martinez

Director/Board Member	2010-12-08	2020-12-30
Independent Dir/Board Member	2010-12-05	2020-12-30

Raj Prabhakar

Corporate Officer/Principal

2009-12-06

2015-06-30

Harriet Shelare

Public Communications Contact

2015-04-26

Max E. Link

Chairman	1997-01-01	2014-10-04
Independent Dir/Board Member	1997-01-01	2014-10-04

Gregory Weaver

Director of Finance/CFO

2011-07-12

2013-06-29

Frank Gary Renshaw

Chief Tech/Sci/R&D Officer	2011-08-29	-
Director/Board Member	-	-

Gary Pace

Director/Board Member

2001-12-31

2010-07-28

Sean Moran

Director of Finance/CFO

2008-11-30

2010-01-07

Robert A. Reed

Corporate Officer/Principal

2009-12-06

Timothy Tumminello

Comptroller/Controller/Auditor

2010-01-10

Paul B. Susie

Director of Finance/CFO

2007-02-18

2008-11-23

Kris Venkat

Director/Board Member

2001-04-30

2008-03-01

William F. Hahne

Chief Tech/Sci/R&D Officer

2005-12-31

2007-11-30

Anthony P. Deasey

Chief Operating Officer	2000-10-31	2007-09-29
Director of Finance/CFO	2000-10-31	2007-09-29
Corporate Secretary	2000-10-31	2007-09-29

Mark Italia

General Counsel

2007-02-28

Lawrence Olanoff

Director/Board Member	2005-07-28	2006-10-05
Chief Executive Officer	2005-07-28	2006-10-05
President	2005-07-28	2006-10-05

Claude Tihon

Director/Board Member

2006-05-26

Yim-Pan Cheung

Director/Board Member	1996-12-31	2006-02-28
Chief Tech/Sci/R&D Officer	1996-12-31	2006-01-15
Founder	1981-12-31	2006-02-28

Douglas Liu

Director of Finance/CFO

1995-12-31

2004-12-31

Michael Oleck

Chief Operating Officer

2004-08-31

Spencer J. Volk

Director/Board Member	1997-05-21	2001-10-03
Chief Executive Officer	1997-05-21	2001-10-03
President	1997-05-21	2001-10-03

Verle D. Blaha

Director/Board Member	1996-09-05	1997-04-22
Chief Executive Officer	1996-09-05	1997-04-22
President	1996-09-05	1997-04-22

Susan Garland

Public Communications Contact

David Hicks

Corporate Officer/Principal

Carolyn Finkle

General Counsel

Dennis Smith

Corporate Officer/Principal

John Mon

Director/Board Member	-	-
Corporate Officer/Principal	-	-

David J. Braitman

Corporate Officer/Principal

William Gannon

Corporate Officer/Principal

Anita Jo Finkelstein

General Counsel

Age distribution of managers

Parity Men Women

Male	8
Female	2

Of which Executive Committee

Male	4
Female	1

Of which Directors

Male	5
Female	1

ESG MSCI

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-26 - Q4 2024 Earnings Release (Projected)

More about the company